KR20030038692A - 비-이미다졸 아릴옥시알킬아민 - Google Patents
비-이미다졸 아릴옥시알킬아민 Download PDFInfo
- Publication number
- KR20030038692A KR20030038692A KR10-2003-7001878A KR20037001878A KR20030038692A KR 20030038692 A KR20030038692 A KR 20030038692A KR 20037001878 A KR20037001878 A KR 20037001878A KR 20030038692 A KR20030038692 A KR 20030038692A
- Authority
- KR
- South Korea
- Prior art keywords
- piperidin
- propoxy
- benzyl
- phenyl
- amine
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title description 16
- 239000000203 mixture Substances 0.000 claims abstract description 116
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 44
- 229960001340 histamine Drugs 0.000 claims abstract description 32
- 230000001404 mediated effect Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 361
- -1 nitro, hydroxyl Chemical group 0.000 claims description 335
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 81
- 125000000623 heterocyclic group Chemical group 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 125000002947 alkylene group Chemical group 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 102000005962 receptors Human genes 0.000 claims description 24
- 108020003175 receptors Proteins 0.000 claims description 24
- 125000005936 piperidyl group Chemical group 0.000 claims description 21
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 125000002883 imidazolyl group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000004193 piperazinyl group Chemical group 0.000 claims description 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- JSJYDVDQYODMDX-UHFFFAOYSA-N n,n-dibenzyl-3-[2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrrol-1-yl]propan-1-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C1=CC=CN1CCCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 JSJYDVDQYODMDX-UHFFFAOYSA-N 0.000 claims description 7
- IKVLVLHDFWSKRB-UHFFFAOYSA-N n,n-dimethyl-1-[4-(3-piperidin-1-ylpropoxy)phenyl]methanamine Chemical compound C1=CC(CN(C)C)=CC=C1OCCCN1CCCCC1 IKVLVLHDFWSKRB-UHFFFAOYSA-N 0.000 claims description 7
- BLOYGYOEWOXMLK-UHFFFAOYSA-N n-[[3-(3-piperidin-1-ylpropoxy)phenyl]methyl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=1)=CC=CC=1CNC1=CC=CC=N1 BLOYGYOEWOXMLK-UHFFFAOYSA-N 0.000 claims description 7
- YGOIFRUGFXCGRG-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C=1C=C(CNC2C3=CC=CC=C3CC2)C=CC=1OCCCN1CCCCC1 YGOIFRUGFXCGRG-UHFFFAOYSA-N 0.000 claims description 7
- PLTZXAGYCBQZDE-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]aniline Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CNC1=CC=CC=C1 PLTZXAGYCBQZDE-UHFFFAOYSA-N 0.000 claims description 7
- VMBGKHZBGBIRGK-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]cyclohexanamine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CNC1CCCCC1 VMBGKHZBGBIRGK-UHFFFAOYSA-N 0.000 claims description 7
- AHXDVXPTBXDCAS-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CNC1=CC=CC=N1 AHXDVXPTBXDCAS-UHFFFAOYSA-N 0.000 claims description 7
- TVNMRGWPBXIDJZ-UHFFFAOYSA-N n-methyl-1-phenyl-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]methanamine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1CN(C)CC1=CC=CC=C1 TVNMRGWPBXIDJZ-UHFFFAOYSA-N 0.000 claims description 7
- ZZVAHJMTBCKCHT-UHFFFAOYSA-N n-methyl-2-phenyl-n-[[3-(3-piperidin-1-ylpropoxy)phenyl]methyl]ethanamine Chemical compound C=1C=CC(OCCCN2CCCCC2)=CC=1CN(C)CCC1=CC=CC=C1 ZZVAHJMTBCKCHT-UHFFFAOYSA-N 0.000 claims description 7
- PGBITHGBHDQJGO-UHFFFAOYSA-N n-methyl-2-phenyl-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1CN(C)CCC1=CC=CC=C1 PGBITHGBHDQJGO-UHFFFAOYSA-N 0.000 claims description 7
- MIPLPVXNQOMIER-UHFFFAOYSA-N n-methyl-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-2-pyridin-2-ylethanamine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1CN(C)CCC1=CC=CC=N1 MIPLPVXNQOMIER-UHFFFAOYSA-N 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- ZJNCDCUEPRDQOY-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methyl-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]ethanamine Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CC(C=C1)=CC=C1OCCCN1CCCCC1 ZJNCDCUEPRDQOY-UHFFFAOYSA-N 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- WYHGHNUOJGEIJD-UHFFFAOYSA-N n,1-dimethyl-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-amine Chemical compound C1CN(C)CCC1N(C)CC(C=C1)=CC=C1OCCCN1CCCCC1 WYHGHNUOJGEIJD-UHFFFAOYSA-N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- ZPCVCFDRDATZRL-UHFFFAOYSA-N 1-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]benzimidazole Chemical compound C=1C=C(CN2CCC(CC2)N2C3=CC=CC=C3N=C2)C=CC=1OCCCN1CCCCC1 ZPCVCFDRDATZRL-UHFFFAOYSA-N 0.000 claims description 5
- ACTWRDRKIGWKNM-UHFFFAOYSA-N 1-[3-[1-[4-(3-piperidin-1-ylpropoxy)phenyl]tetrazol-5-yl]sulfanylpropyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1N1N=NN=C1SCCCN1CCCCC1 ACTWRDRKIGWKNM-UHFFFAOYSA-N 0.000 claims description 5
- LBKGMCRQDLMDRQ-UHFFFAOYSA-N 1-[3-[2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrrol-1-yl]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C1=CC=CN1CCCN1CCCCC1 LBKGMCRQDLMDRQ-UHFFFAOYSA-N 0.000 claims description 5
- VGLPYKFBKXTZIJ-UHFFFAOYSA-N 1-[3-[4-(1-methylpyrrolidin-2-yl)phenoxy]propyl]piperidine Chemical compound CN1CCCC1C(C=C1)=CC=C1OCCCN1CCCCC1 VGLPYKFBKXTZIJ-UHFFFAOYSA-N 0.000 claims description 5
- SIOSEBZEOBJIQU-UHFFFAOYSA-N 1-[3-[4-(pyrrolidin-1-ylmethyl)phenoxy]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCC1 SIOSEBZEOBJIQU-UHFFFAOYSA-N 0.000 claims description 5
- REJHWHKAYIUXPP-UHFFFAOYSA-N 1-[3-[4-[2-(piperidin-1-ylmethyl)phenyl]phenoxy]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C1=CC=CC=C1CN1CCCCC1 REJHWHKAYIUXPP-UHFFFAOYSA-N 0.000 claims description 5
- MFYYWQBRMXAKIQ-UHFFFAOYSA-N 1-[4-(3-piperidin-1-ylpropoxy)phenyl]-4-propan-2-ylpiperazine Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OCCCN1CCCCC1 MFYYWQBRMXAKIQ-UHFFFAOYSA-N 0.000 claims description 5
- WFNAXSJCNYTFJY-UHFFFAOYSA-N 1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-3,4-dihydro-2h-quinoline Chemical compound C=1C=C(CN2C3=CC=CC=C3CCC2)C=CC=1OCCCN1CCCCC1 WFNAXSJCNYTFJY-UHFFFAOYSA-N 0.000 claims description 5
- XFAHPWLMTTVWQF-UHFFFAOYSA-N 1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-4-propan-2-ylpiperazine Chemical compound C1CN(C(C)C)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 XFAHPWLMTTVWQF-UHFFFAOYSA-N 0.000 claims description 5
- BTRRJPQFQGJPEC-UHFFFAOYSA-N 1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-azacyclotridecane Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCCCCCCCCC1 BTRRJPQFQGJPEC-UHFFFAOYSA-N 0.000 claims description 5
- DICHVUOTONTMRI-UHFFFAOYSA-N 1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 DICHVUOTONTMRI-UHFFFAOYSA-N 0.000 claims description 5
- AODYXYIABDOJKK-UHFFFAOYSA-N 1-benzyl-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(OCCCN3CCCCC3)=CC=2)CCN1CC1=CC=CC=C1 AODYXYIABDOJKK-UHFFFAOYSA-N 0.000 claims description 5
- MYXFDXYHZXLCTN-UHFFFAOYSA-N 1-benzyl-4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1 MYXFDXYHZXLCTN-UHFFFAOYSA-N 0.000 claims description 5
- ZJINMHMBYYCSPS-UHFFFAOYSA-N 1-benzyl-4-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperazine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCN1CC1=CC=CC=C1 ZJINMHMBYYCSPS-UHFFFAOYSA-N 0.000 claims description 5
- CGFMRMTVXXMSJR-UHFFFAOYSA-N 1-methyl-4-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperazine Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 CGFMRMTVXXMSJR-UHFFFAOYSA-N 0.000 claims description 5
- LAKBEIFFRRZHDV-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C1=CC(Cl)=CC=C1N1C(CN2CC=3C=CC(OCCCN4CCCCC4)=CC=3)CC2C1 LAKBEIFFRRZHDV-UHFFFAOYSA-N 0.000 claims description 5
- AMDYHZFFHGQUTP-UHFFFAOYSA-N 2-methyl-1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidine Chemical compound CC1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 AMDYHZFFHGQUTP-UHFFFAOYSA-N 0.000 claims description 5
- LDXIGZPJQJCJJY-UHFFFAOYSA-N 4-(3-phenylpropyl)-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC1CCCC1=CC=CC=C1 LDXIGZPJQJCJJY-UHFFFAOYSA-N 0.000 claims description 5
- SWBLVOLQPQNGMO-UHFFFAOYSA-N 4-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]morpholine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCOCC1 SWBLVOLQPQNGMO-UHFFFAOYSA-N 0.000 claims description 5
- SRZKSKAKSQZZRQ-UHFFFAOYSA-N 4-benzyl-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC1CC1=CC=CC=C1 SRZKSKAKSQZZRQ-UHFFFAOYSA-N 0.000 claims description 5
- VSSKQAKVRWUHNC-UHFFFAOYSA-N 4-benzylidene-1-[[3-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine Chemical compound C1CCCCN1CCCOC(C=1)=CC=CC=1CN(CC1)CCC1=CC1=CC=CC=C1 VSSKQAKVRWUHNC-UHFFFAOYSA-N 0.000 claims description 5
- ZTVHXLUFCRGQAC-UHFFFAOYSA-N 4-benzylidene-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC1=CC1=CC=CC=C1 ZTVHXLUFCRGQAC-UHFFFAOYSA-N 0.000 claims description 5
- ISGCVXFRVJDDIM-UHFFFAOYSA-N 4-chloro-n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]aniline Chemical compound C1=CC(Cl)=CC=C1NCC(C=C1)=CC=C1OCCCN1CCCCC1 ISGCVXFRVJDDIM-UHFFFAOYSA-N 0.000 claims description 5
- TXKVKYMFOVDJAZ-UHFFFAOYSA-N 4-phenyl-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC=CC=2)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 TXKVKYMFOVDJAZ-UHFFFAOYSA-N 0.000 claims description 5
- CGGCIKBZDQRRKK-UHFFFAOYSA-N 5-bromo-1-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]-2,3-dihydroindole Chemical compound C1CC2=CC(Br)=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 CGGCIKBZDQRRKK-UHFFFAOYSA-N 0.000 claims description 5
- ZGAZKQWQIOPMTC-UHFFFAOYSA-N 8-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC21OCCO2 ZGAZKQWQIOPMTC-UHFFFAOYSA-N 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000020358 Learning disease Diseases 0.000 claims description 5
- 206010028735 Nasal congestion Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 239000000938 histamine H1 antagonist Substances 0.000 claims description 5
- PTKHFRNHJULJKT-UHFFFAOYSA-N jnj-5207852 Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PTKHFRNHJULJKT-UHFFFAOYSA-N 0.000 claims description 5
- 201000003723 learning disability Diseases 0.000 claims description 5
- URTNNMSUOYQSJY-UHFFFAOYSA-N n-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]-n-(2-pyrrolidin-1-ylethyl)pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC1N(C=1N=CC=CC=1)CCN1CCCC1 URTNNMSUOYQSJY-UHFFFAOYSA-N 0.000 claims description 5
- NPGODRPTHLQCAZ-UHFFFAOYSA-N n-methyl-n-(2-phenylethyl)-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-amine Chemical compound C1CN(CC=2C=CC(OCCCN3CCCCC3)=CC=2)CCC1N(C)CCC1=CC=CC=C1 NPGODRPTHLQCAZ-UHFFFAOYSA-N 0.000 claims description 5
- 201000003631 narcolepsy Diseases 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- WAAQKCOEGQEFTH-UHFFFAOYSA-N 1-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]-2,3-dihydroindole Chemical compound C=1C=C(CN2CCC(CC2)N2C3=CC=CC=C3CC2)C=CC=1OCCCN1CCCCC1 WAAQKCOEGQEFTH-UHFFFAOYSA-N 0.000 claims description 4
- OWINJKNPCPHOEX-UHFFFAOYSA-N 1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]piperidine Chemical compound C=1C=C(CN2CCCCC2)C=CC=1OCCN1CCCCC1 OWINJKNPCPHOEX-UHFFFAOYSA-N 0.000 claims description 4
- OZHWKCSDZSJHKE-UHFFFAOYSA-N 1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-ol Chemical compound C1CC(O)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 OZHWKCSDZSJHKE-UHFFFAOYSA-N 0.000 claims description 4
- JGXPRBPQZNTSJO-UHFFFAOYSA-N 1-phenyl-4-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperazine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCN1C1=CC=CC=C1 JGXPRBPQZNTSJO-UHFFFAOYSA-N 0.000 claims description 4
- PRFWGYQTIHQTDG-UHFFFAOYSA-N 2-[1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidin-2-yl]ethanol Chemical compound OCCC1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PRFWGYQTIHQTDG-UHFFFAOYSA-N 0.000 claims description 4
- JPYLIRILYXRRNY-UHFFFAOYSA-N 2-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C=1C=C(CN2CC3=CC=CC=C3CC2)C=CC=1OCCN1CCCCC1 JPYLIRILYXRRNY-UHFFFAOYSA-N 0.000 claims description 4
- IBEFILCHUHYSKH-UHFFFAOYSA-N 2-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C=1C=C(CN2CC3=CC=CC=C3CC2)C=CC=1OCCCN1CCCCC1 IBEFILCHUHYSKH-UHFFFAOYSA-N 0.000 claims description 4
- AWOTWPMBZGZKGR-UHFFFAOYSA-N 3-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 AWOTWPMBZGZKGR-UHFFFAOYSA-N 0.000 claims description 4
- WSFBJZICJNTMPV-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 WSFBJZICJNTMPV-UHFFFAOYSA-N 0.000 claims description 4
- IADDLPIDNNJDGQ-UHFFFAOYSA-N 4-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]morpholine Chemical compound C1COCCN1CCCOC(C=1)=CC=CC=1CN1CCCCC1 IADDLPIDNNJDGQ-UHFFFAOYSA-N 0.000 claims description 4
- KUIIIXUFHYLJSU-UHFFFAOYSA-N 4-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]morpholine Chemical compound C1COCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 KUIIIXUFHYLJSU-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 230000037007 arousal Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 208000002173 dizziness Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- ZFXQFCJVRUTPDS-UHFFFAOYSA-N n-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN(CC1)CCC1NC1=CC=CC=N1 ZFXQFCJVRUTPDS-UHFFFAOYSA-N 0.000 claims description 4
- UWYBQECMDSLCLH-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-n-(pyridin-4-ylmethyl)ethanamine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1CN(CC)CC1=CC=NC=C1 UWYBQECMDSLCLH-UHFFFAOYSA-N 0.000 claims description 4
- BREBRNZBFVXXJN-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]cyclopropanamine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CNC1CC1 BREBRNZBFVXXJN-UHFFFAOYSA-N 0.000 claims description 4
- VTBBTNTUEKFKMS-UHFFFAOYSA-N n-[[4-(3-pyrrolidin-1-ylpropoxy)phenyl]methyl]pyridin-2-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1CNC1=CC=CC=N1 VTBBTNTUEKFKMS-UHFFFAOYSA-N 0.000 claims description 4
- DGIUGQNITWRNDW-UHFFFAOYSA-N n-benzyl-n-methyl-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-amine Chemical compound C1CN(CC=2C=CC(OCCCN3CCCCC3)=CC=2)CCC1N(C)CC1=CC=CC=C1 DGIUGQNITWRNDW-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- MNVIMOXZHWYWAP-UHFFFAOYSA-N 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine;hydrochloride Chemical compound Cl.C1CCCCN1CCCOC(C=C1)=CC=C1N1CCNCC1 MNVIMOXZHWYWAP-UHFFFAOYSA-N 0.000 claims description 3
- XXKOYFOKVFBPJR-UHFFFAOYSA-N 1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazine;hydrochloride Chemical compound Cl.C1CCCN1CCCOC(C=C1)=CC=C1N1CCNCC1 XXKOYFOKVFBPJR-UHFFFAOYSA-N 0.000 claims description 3
- BNIODALAVHNQQG-UHFFFAOYSA-N 1-methyl-4-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperazine Chemical compound C1CN(C)CCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 BNIODALAVHNQQG-UHFFFAOYSA-N 0.000 claims description 3
- AMYTVKNRWISIJL-UHFFFAOYSA-N 3-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-2-yl]pyridine Chemical group C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1C1=CC=CN=C1 AMYTVKNRWISIJL-UHFFFAOYSA-N 0.000 claims description 3
- ITUITYSGAVRXSE-UHFFFAOYSA-N 4-chloro-n-[[3-(3-piperidin-1-ylpropoxy)phenyl]methyl]aniline Chemical compound C1=CC(Cl)=CC=C1NCC1=CC=CC(OCCCN2CCCCC2)=C1 ITUITYSGAVRXSE-UHFFFAOYSA-N 0.000 claims description 3
- KNMCEICODBFYMR-UHFFFAOYSA-N 5-(3-piperidin-1-ylpropoxy)-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrimidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C(N=C1)=NC=C1OCCCN1CCCCC1 KNMCEICODBFYMR-UHFFFAOYSA-N 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- RKCRYTQBGHXCRT-UHFFFAOYSA-N n,n-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenoxy]ethanamine Chemical compound C1=CC(OCCN(C)C)=CC=C1OCCCN1CCCCC1 RKCRYTQBGHXCRT-UHFFFAOYSA-N 0.000 claims description 3
- QUUUOVGZDVVVGL-UHFFFAOYSA-N n,n-dimethyl-3-[4-(piperidin-1-ylmethyl)phenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(C)C)=CC=C1CN1CCCCC1 QUUUOVGZDVVVGL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 238000002600 positron emission tomography Methods 0.000 claims description 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- TXJIYPJAMHRJHM-UHFFFAOYSA-N 1-[3-[4-[2-(1-methylpyrrolidin-2-yl)ethyl]phenoxy]propyl]piperidine Chemical compound CN1CCCC1CCC(C=C1)=CC=C1OCCCN1CCCCC1 TXJIYPJAMHRJHM-UHFFFAOYSA-N 0.000 claims description 2
- HMONAGSLOSCNIG-UHFFFAOYSA-N 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1N1CCNCC1 HMONAGSLOSCNIG-UHFFFAOYSA-N 0.000 claims description 2
- BWHPNLXFRFLDNW-UHFFFAOYSA-N 1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1N1CCNCC1 BWHPNLXFRFLDNW-UHFFFAOYSA-N 0.000 claims description 2
- VTCPVDKYTHLWFB-UHFFFAOYSA-N 1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-3,4-dihydro-2h-quinoline Chemical compound C=1C=C(CN2C3=CC=CC=C3CCC2)C=CC=1OCCN1CCCCC1 VTCPVDKYTHLWFB-UHFFFAOYSA-N 0.000 claims description 2
- QXAJVWZJJUVWMH-UHFFFAOYSA-N 3-(furan-2-yl)-n,n-dimethyl-3-[4-(3-piperidin-1-ylpropoxy)phenyl]propan-1-amine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1C(CCN(C)C)C1=CC=CO1 QXAJVWZJJUVWMH-UHFFFAOYSA-N 0.000 claims description 2
- OQTFRJFAPYRPGR-UHFFFAOYSA-N 4-[2-[4-(3-piperidin-1-ylpropoxy)phenyl]phenyl]-1-propan-2-ylpiperidine Chemical compound C1CN(C(C)C)CCC1C1=CC=CC=C1C(C=C1)=CC=C1OCCCN1CCCCC1 OQTFRJFAPYRPGR-UHFFFAOYSA-N 0.000 claims description 2
- LXHKXZXFYGXUDK-UHFFFAOYSA-N 4-[3-[4-(3-piperidin-1-ylpropoxy)phenyl]-3-pyrimidin-2-ylpropyl]morpholine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C(C=1N=CC=CN=1)CCN1CCOCC1 LXHKXZXFYGXUDK-UHFFFAOYSA-N 0.000 claims description 2
- ROYPFDGCIUUZMH-UHFFFAOYSA-N 4-[4,4,4-trifluoro-3-[4-(3-piperidin-1-ylpropoxy)phenyl]butyl]morpholine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1C(C(F)(F)F)CCN1CCOCC1 ROYPFDGCIUUZMH-UHFFFAOYSA-N 0.000 claims description 2
- RGIYHEYZFULOEE-UHFFFAOYSA-N 4-[4-(3-piperidin-1-ylpropoxy)phenyl]-1-propan-2-ylpiperidin-4-ol Chemical compound C1CN(C(C)C)CCC1(O)C(C=C1)=CC=C1OCCCN1CCCCC1 RGIYHEYZFULOEE-UHFFFAOYSA-N 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- GEBSUCYNZQGTBV-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-4-(3-piperidin-1-ylpropoxy)-n-propan-2-ylaniline Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1N(C(C)C)CCN1CCOCC1 GEBSUCYNZQGTBV-UHFFFAOYSA-N 0.000 claims description 2
- GIEUISVRUOESON-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-n-[4-(3-piperidin-1-ylpropoxy)phenyl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1N(C=1N=CC=CC=1)CCN1CCOCC1 GIEUISVRUOESON-UHFFFAOYSA-N 0.000 claims description 2
- MKPIMPHUZOVAFF-UHFFFAOYSA-N n-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-n-propylpyridin-4-amine Chemical compound C=1C=NC=CC=1N(CCC)CC(C=C1)=CC=C1OCCCN1CCCCC1 MKPIMPHUZOVAFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 150000003956 methylamines Chemical class 0.000 claims 1
- 239000003068 molecular probe Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 458
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 195
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 123
- 239000000243 solution Substances 0.000 description 100
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 94
- 239000000047 product Substances 0.000 description 84
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 78
- 239000012074 organic phase Substances 0.000 description 75
- 235000011054 acetic acid Nutrition 0.000 description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 55
- 239000012230 colorless oil Substances 0.000 description 49
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 47
- 235000019341 magnesium sulphate Nutrition 0.000 description 47
- 238000004587 chromatography analysis Methods 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- 229910052938 sodium sulfate Inorganic materials 0.000 description 37
- 235000011152 sodium sulphate Nutrition 0.000 description 37
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 30
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 30
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 29
- 239000007787 solid Substances 0.000 description 29
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 125000006239 protecting group Chemical group 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 8
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 235000015424 sodium Nutrition 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- 102000000543 Histamine Receptors Human genes 0.000 description 6
- 108010002059 Histamine Receptors Proteins 0.000 description 6
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical group CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- APNWHXAYLQEXJG-UHFFFAOYSA-N 2-(3-piperidin-1-ylpropoxy)benzaldehyde Chemical compound O=CC1=CC=CC=C1OCCCN1CCCCC1 APNWHXAYLQEXJG-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QMQNIKYRPSFQKB-UHFFFAOYSA-N 4-benzylidenepiperidine Chemical compound C1CNCCC1=CC1=CC=CC=C1 QMQNIKYRPSFQKB-UHFFFAOYSA-N 0.000 description 3
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 235000021186 dishes Nutrition 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- WWMSKBGEBHMHEP-UHFFFAOYSA-N 1-(3-chloropropoxy)-4-iodobenzene Chemical compound ClCCCOC1=CC=C(I)C=C1 WWMSKBGEBHMHEP-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- LIYAXYWIPFSTND-UHFFFAOYSA-N 1-benzyl-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1 LIYAXYWIPFSTND-UHFFFAOYSA-N 0.000 description 2
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 2
- GSPAVZIEDMALNO-UHFFFAOYSA-N 1-piperidin-2-ylethanol Chemical compound CC(O)C1CCCCN1 GSPAVZIEDMALNO-UHFFFAOYSA-N 0.000 description 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- HNJWKRMESUMDQE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- OVDJDGHFBGJJHZ-UHFFFAOYSA-N 2-[1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-yl]ethanol Chemical compound C1CC(CCO)CCN1CC(C=C1)=CC=C1OCCCN1CCCCC1 OVDJDGHFBGJJHZ-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 2
- PLRXAFVBCHEMGD-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-ol Chemical compound OCCCN1CCCCC1 PLRXAFVBCHEMGD-UHFFFAOYSA-N 0.000 description 2
- NXSSPESTEGMASS-UHFFFAOYSA-N 4-(2-piperidin-2-ylethoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCC1NCCCC1 NXSSPESTEGMASS-UHFFFAOYSA-N 0.000 description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- KZTWONRVIPPDKH-UHFFFAOYSA-N hydroxyethyl piperidine Natural products OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- YLKHAMLPZAGCGO-UHFFFAOYSA-N 1,1,1-trichloro-3-(4-methoxyphenyl)hepta-2,5-dien-4-one Chemical compound COC1=CC=C(C(=CC(Cl)(Cl)Cl)C(=O)[C-]=CC)C=C1 YLKHAMLPZAGCGO-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- SMWUDAKKCDQTPV-UHFFFAOYSA-N 1,3-dimethylimidazolidine Chemical compound CN1CCN(C)C1 SMWUDAKKCDQTPV-UHFFFAOYSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- RWYYNSXVFPESMC-UHFFFAOYSA-N 1,5-dihydro-2,4-benzodioxepine Chemical compound C1OCOCC2=CC=CC=C21 RWYYNSXVFPESMC-UHFFFAOYSA-N 0.000 description 1
- BKBUBAVZGMRPAK-UHFFFAOYSA-N 1-(3-bromopropyl)-2,2,5,5-tetramethyl-1,2,5-azadisilolidine Chemical compound C[Si]1(C)CC[Si](C)(C)N1CCCBr BKBUBAVZGMRPAK-UHFFFAOYSA-N 0.000 description 1
- GIXCXAMRCRRNOO-UHFFFAOYSA-N 1-(3-chloropropoxy)cyclohexa-2,4-diene-1-carbaldehyde Chemical compound ClCCCOC1(C=O)CC=CC=C1 GIXCXAMRCRRNOO-UHFFFAOYSA-N 0.000 description 1
- HDDNBUNZJIQDBQ-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine Chemical compound ClCCCN1CCCCC1 HDDNBUNZJIQDBQ-UHFFFAOYSA-N 0.000 description 1
- MOXZSKYLLSPATM-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-2h-tetrazole-5-thione Chemical compound C1=CC(O)=CC=C1N1C(=S)N=NN1 MOXZSKYLLSPATM-UHFFFAOYSA-N 0.000 description 1
- WGEIOMTZIIOUMA-QPJJXVBHSA-N 1-[(e)-3-phenylprop-2-enyl]piperazine Chemical compound C1CNCCN1C\C=C\C1=CC=CC=C1 WGEIOMTZIIOUMA-QPJJXVBHSA-N 0.000 description 1
- SBZXROKCONSCHA-UHFFFAOYSA-N 1-[3-(4-iodophenoxy)propyl]piperidine Chemical compound C1=CC(I)=CC=C1OCCCN1CCCCC1 SBZXROKCONSCHA-UHFFFAOYSA-N 0.000 description 1
- ZHTQDAFKFNIAEJ-UHFFFAOYSA-N 1-[3-(4-phenylmethoxyphenoxy)propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1OCC1=CC=CC=C1 ZHTQDAFKFNIAEJ-UHFFFAOYSA-N 0.000 description 1
- AALWEDAITLAZMV-UHFFFAOYSA-N 1-[3-[4-(1h-pyrrol-2-yl)phenoxy]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C1=CC=CN1 AALWEDAITLAZMV-UHFFFAOYSA-N 0.000 description 1
- NDFWRVXCPJKCAB-UHFFFAOYSA-N 1-[3-[4-(2-piperidin-1-ylethoxy)phenoxy]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1OCCN1CCCCC1 NDFWRVXCPJKCAB-UHFFFAOYSA-N 0.000 description 1
- AVEAVFNZFPGFPC-UHFFFAOYSA-N 1-[3-[4-(3-piperidin-1-ylpropoxy)phenoxy]propyl]piperidine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1OCCCN1CCCCC1 AVEAVFNZFPGFPC-UHFFFAOYSA-N 0.000 description 1
- ZFCVHEWMUKQJFF-UHFFFAOYSA-N 1-[[4-(3-chloropropoxy)phenyl]methyl]piperidine Chemical compound C1=CC(OCCCCl)=CC=C1CN1CCCCC1 ZFCVHEWMUKQJFF-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- ATPQHBQUXWELOE-UHFFFAOYSA-N 1-hydroxysulfanyl-2,4-dinitrobenzene Chemical compound OSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O ATPQHBQUXWELOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- HTXSCMQHTMIMTD-UHFFFAOYSA-N 1-piperidin-4-yl-2,3-dihydroindole Chemical compound C1CC2=CC=CC=C2N1C1CCNCC1 HTXSCMQHTMIMTD-UHFFFAOYSA-N 0.000 description 1
- QYCKVZZMAXDBHQ-UHFFFAOYSA-N 1-piperidin-4-ylbenzimidazole Chemical compound C1CNCCC1N1C2=CC=CC=C2N=C1 QYCKVZZMAXDBHQ-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- IPKOJSMGLIKFLO-UHFFFAOYSA-N 2,2,5,5-tetramethyl-1,2,5-azadisilolidine Chemical group C[Si]1(C)CC[Si](C)(C)N1 IPKOJSMGLIKFLO-UHFFFAOYSA-N 0.000 description 1
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical compound C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 description 1
- YAIUOMMSSSVJLB-UHFFFAOYSA-N 2-(1,3-dioxan-5-yl)pyridine Chemical compound C1OCOCC1C1=CC=CC=N1 YAIUOMMSSSVJLB-UHFFFAOYSA-N 0.000 description 1
- BKOPBDRWHKDPPN-UHFFFAOYSA-N 2-(4-hydroxyphenyl)pyrimidin-5-ol Chemical compound C1=CC(O)=CC=C1C1=NC=C(O)C=N1 BKOPBDRWHKDPPN-UHFFFAOYSA-N 0.000 description 1
- KFXDYZXVIHNBFD-UHFFFAOYSA-N 2-(thian-2-ylsulfonyl)thiane Chemical compound C1CCCSC1S(=O)(=O)C1CCCCS1 KFXDYZXVIHNBFD-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- DBZOCYUGXIJCQH-UHFFFAOYSA-N 2-[4-(3-piperidin-1-ylpropoxy)phenyl]benzaldehyde Chemical compound O=CC1=CC=CC=C1C(C=C1)=CC=C1OCCCN1CCCCC1 DBZOCYUGXIJCQH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- SCJVENAJIYSJTK-UHFFFAOYSA-N 2-methyl-4-piperidin-1-ylphenol Chemical compound C1=C(O)C(C)=CC(N2CCCCC2)=C1 SCJVENAJIYSJTK-UHFFFAOYSA-N 0.000 description 1
- JWHHNSIZTDYRCL-UHFFFAOYSA-N 2-methylbutan-2-yl 2-phenoxyacetate Chemical compound CCC(C)(C)OC(=O)COC1=CC=CC=C1 JWHHNSIZTDYRCL-UHFFFAOYSA-N 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- NCZNFFWWTMEIHC-UHFFFAOYSA-N 2-phenyl-2,5-diazabicyclo[2.2.1]heptane;hydrobromide Chemical compound Br.C1NC(C2)CC1N2C1=CC=CC=C1 NCZNFFWWTMEIHC-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
- JNSUUJLFWBSBME-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)propan-1-ol Chemical compound CC1CCCCN1CCCO JNSUUJLFWBSBME-UHFFFAOYSA-N 0.000 description 1
- IXNHDPVJSRAWGR-UHFFFAOYSA-N 3-(3-chloropropoxy)benzaldehyde Chemical compound ClCCCOC1=CC=CC(C=O)=C1 IXNHDPVJSRAWGR-UHFFFAOYSA-N 0.000 description 1
- VRFBHRVCCZPEFY-UHFFFAOYSA-N 3-(3-piperidin-1-ylpropoxy)benzaldehyde Chemical compound O=CC1=CC=CC(OCCCN2CCCCC2)=C1 VRFBHRVCCZPEFY-UHFFFAOYSA-N 0.000 description 1
- WKCYFSZDBICRKL-UHFFFAOYSA-N 3-(diethylamino)propan-1-ol Chemical compound CCN(CC)CCCO WKCYFSZDBICRKL-UHFFFAOYSA-N 0.000 description 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 1
- UOQHRZYJHNODNL-UHFFFAOYSA-N 4,5-bis(methoxymethyl)-1,3-dioxolane Chemical compound COCC1OCOC1COC UOQHRZYJHNODNL-UHFFFAOYSA-N 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- UXWLHPWCZJEEDL-UHFFFAOYSA-N 4-(2-nitrophenyl)-1,3-dioxolane Chemical compound [O-][N+](=O)C1=CC=CC=C1C1OCOC1 UXWLHPWCZJEEDL-UHFFFAOYSA-N 0.000 description 1
- CKGQJZWAOFNWQT-UHFFFAOYSA-N 4-(3-chloropropoxy)benzaldehyde Chemical compound ClCCCOC1=CC=C(C=O)C=C1 CKGQJZWAOFNWQT-UHFFFAOYSA-N 0.000 description 1
- HASRFXGIJALRRB-UHFFFAOYSA-N 4-(3-phenylpropyl)piperidine Chemical compound C=1C=CC=CC=1CCCC1CCNCC1 HASRFXGIJALRRB-UHFFFAOYSA-N 0.000 description 1
- LKFZIDIRWPHNEA-UHFFFAOYSA-N 4-(3-piperidin-1-ylpropoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCCN1CCCCC1 LKFZIDIRWPHNEA-UHFFFAOYSA-N 0.000 description 1
- WXUZSTVHUILKOE-UHFFFAOYSA-N 4-(3-piperidin-1-ylpropoxy)phenol Chemical compound C1=CC(O)=CC=C1OCCCN1CCCCC1 WXUZSTVHUILKOE-UHFFFAOYSA-N 0.000 description 1
- JCSYPJCZYHQVKN-UHFFFAOYSA-N 4-(3-pyrrolidin-1-ylpropoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCCN1CCCC1 JCSYPJCZYHQVKN-UHFFFAOYSA-N 0.000 description 1
- LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 1
- FBWVWZVTOLXWNG-UHFFFAOYSA-N 4-(4-hydroxyphenyl)piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C1=CC=C(O)C=C1 FBWVWZVTOLXWNG-UHFFFAOYSA-N 0.000 description 1
- BLAURXPHWHQJKX-UHFFFAOYSA-N 4-(bromomethyl)-1,3-dioxolane Chemical compound BrCC1COCO1 BLAURXPHWHQJKX-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- DSHNDBHNBSRKFL-UHFFFAOYSA-N 4-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]morpholine;dihydrochloride Chemical compound Cl.Cl.C1COCCN1CCCOC(C=1)=CC=CC=1CN1CCCCC1 DSHNDBHNBSRKFL-UHFFFAOYSA-N 0.000 description 1
- SIWDFEITMRSDBX-UHFFFAOYSA-N 4-[4-(3-chloropropoxy)phenyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C1=CC=C(OCCCCl)C=C1 SIWDFEITMRSDBX-UHFFFAOYSA-N 0.000 description 1
- MYHWMBYFFXZMGL-UHFFFAOYSA-N 4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C(C=C1)=CC=C1OCCCN1CCCCC1 MYHWMBYFFXZMGL-UHFFFAOYSA-N 0.000 description 1
- QCHQOQAUUZXJBC-UHFFFAOYSA-N 4-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]-1-propan-2-ylpiperidine Chemical compound C1CN(C(C)C)CCC1CC(C=C1)=CC=C1OCCCN1CCCCC1 QCHQOQAUUZXJBC-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- DVKIVCPCGXORFD-UHFFFAOYSA-N 4-benzylidene-1-[[2-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidine Chemical compound C1CCCCN1CCCOC1=CC=CC=C1CN(CC1)CCC1=CC1=CC=CC=C1 DVKIVCPCGXORFD-UHFFFAOYSA-N 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- RJTDVQUMWKUFAK-UHFFFAOYSA-N 4-but-3-enyl-1,3-dioxolane Chemical compound C=CCCC1COCO1 RJTDVQUMWKUFAK-UHFFFAOYSA-N 0.000 description 1
- JHJKZRVBRMFGST-UHFFFAOYSA-N 4-chloro-n-[[2-(3-piperidin-1-ylpropoxy)phenyl]methyl]aniline Chemical compound C1=CC(Cl)=CC=C1NCC1=CC=CC=C1OCCCN1CCCCC1 JHJKZRVBRMFGST-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
- OVKDCYKVNYLEHK-UHFFFAOYSA-N 4-phenyl-1,3-dioxolane Chemical compound O1COCC1C1=CC=CC=C1 OVKDCYKVNYLEHK-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 1
- GPEOAEVZTOQXLG-UHFFFAOYSA-N 4-piperazin-1-ium-1-ylphenolate Chemical compound C1=CC(O)=CC=C1N1CCNCC1 GPEOAEVZTOQXLG-UHFFFAOYSA-N 0.000 description 1
- NTCIAFWCCFAZLW-UHFFFAOYSA-N 5,5-dibromo-1,3-dioxane Chemical compound BrC1(Br)COCOC1 NTCIAFWCCFAZLW-UHFFFAOYSA-N 0.000 description 1
- SLPTXXAPGOZOSE-UHFFFAOYSA-N 5-bromo-1-piperidin-4-yl-2,3-dihydroindole Chemical compound C1CC2=CC(Br)=CC=C2N1C1CCNCC1 SLPTXXAPGOZOSE-UHFFFAOYSA-N 0.000 description 1
- JLECSPKJBGOVBW-UHFFFAOYSA-N 5-methylidene-1,3-dioxane Chemical compound C=C1COCOC1 JLECSPKJBGOVBW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ANEJCWBESACBCT-UHFFFAOYSA-N CC1(C2CCC1(C3C2CC(O3)OP(=O)(O)O)C)C Chemical compound CC1(C2CCC1(C3C2CC(O3)OP(=O)(O)O)C)C ANEJCWBESACBCT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- YNUJBNOVGAUPPQ-UHFFFAOYSA-N N,N-bis(2-phenylethyl)-1-[[4-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperidin-4-amine Chemical compound C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CCC(CC3)N(CCC4=CC=CC=C4)CCC5=CC=CC=C5 YNUJBNOVGAUPPQ-UHFFFAOYSA-N 0.000 description 1
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001440143 Panula Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZWGMJLNXIVRFRJ-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrol-2-yl]boronic acid Chemical compound CC(C)(C)OC(=O)N1C=CC=C1B(O)O ZWGMJLNXIVRFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- MTXSIJUGVMTTMU-UHFFFAOYSA-N anabasine Chemical group N1CCCCC1C1=CC=CN=C1 MTXSIJUGVMTTMU-UHFFFAOYSA-N 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004599 benzpyrazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- KVPFKMBYCSISTN-UHFFFAOYSA-N benzylsulfanylformic acid Chemical compound OC(=O)SCC1=CC=CC=C1 KVPFKMBYCSISTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940119122 clarinex Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000011894 couscous Nutrition 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004586 dihydrobenzopyranyl group Chemical group O1C(CCC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004597 dihydrobenzothiopyranyl group Chemical group S1C(CCC2=C1C=CC=C2)* 0.000 description 1
- WOKPSXJEBSRSAT-UHFFFAOYSA-N dihydrobenzothiopyranyl sulfone group Chemical group S1C(CCC2=C1C=CC=C2)S(=O)(=O)C2SC1=C(CC2)C=CC=C1 WOKPSXJEBSRSAT-UHFFFAOYSA-N 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical group CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
- 125000004614 furo[3,1-b]pyridinyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- NRQNMMBQPIGPTB-UHFFFAOYSA-N methylaluminum Chemical compound [CH3].[Al] NRQNMMBQPIGPTB-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- XRYGCVVVDCEPRL-UHFFFAOYSA-N n,1-dimethylpiperidin-4-amine Chemical compound CNC1CCN(C)CC1 XRYGCVVVDCEPRL-UHFFFAOYSA-N 0.000 description 1
- CZXWJRBEKBQWJO-UHFFFAOYSA-N n,n-diethyl-2-[4-(piperidin-1-ylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CN1CCCCC1 CZXWJRBEKBQWJO-UHFFFAOYSA-N 0.000 description 1
- WZVNVTUWWLRNHR-UHFFFAOYSA-N n,n-diethyl-3-[4-(piperidin-1-ylmethyl)phenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(CC)CC)=CC=C1CN1CCCCC1 WZVNVTUWWLRNHR-UHFFFAOYSA-N 0.000 description 1
- ZBAMQLFFVBPAOX-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)ethanamine Chemical compound CCNCC1=CC=NC=C1 ZBAMQLFFVBPAOX-UHFFFAOYSA-N 0.000 description 1
- GKLFMIQWMAHAOL-UHFFFAOYSA-N n-[[2-(3-piperidin-1-ylpropoxy)phenyl]methyl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC1=CC=CC=C1CNC1=CC=CC=N1 GKLFMIQWMAHAOL-UHFFFAOYSA-N 0.000 description 1
- JQSWRIGANADNJD-UHFFFAOYSA-N n-benzyl-n-methylpiperidin-4-amine Chemical compound C1CNCCC1N(C)CC1=CC=CC=C1 JQSWRIGANADNJD-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- MJXPDBFDHSMVNS-UHFFFAOYSA-N n-methyl-1-pyridin-2-ylethanamine Chemical compound CNC(C)C1=CC=CC=N1 MJXPDBFDHSMVNS-UHFFFAOYSA-N 0.000 description 1
- VMBVZOWXRDYODM-UHFFFAOYSA-N n-methyl-n-(2-phenylethyl)piperidin-4-amine Chemical compound C1CNCCC1N(C)CCC1=CC=CC=C1 VMBVZOWXRDYODM-UHFFFAOYSA-N 0.000 description 1
- SBSLCPHONZWKIE-UHFFFAOYSA-N n-piperidin-4-ylpyridin-2-amine Chemical compound C1CNCCC1NC1=CC=CC=N1 SBSLCPHONZWKIE-UHFFFAOYSA-N 0.000 description 1
- CBKFHSNATJJWQK-UHFFFAOYSA-N n-pyridin-3-ylformamide Chemical class O=CNC1=CC=CN=C1 CBKFHSNATJJWQK-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000004626 naphthothienyl group Chemical group C1(=CSC2=C1C1=CC=CC=C1C=C2)* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical compound CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Abstract
Description
DBAD | = | 디-tert-아조디카복실레이트 |
DCE | = | 1,2-디클로로에탄 |
DCM | = | 디클로로메탄 |
DEAD | = | 디에틸 아조디카복실레이트 |
DMA | = | N,N-디메틸아세트아미드 |
DMAP | = | 4-N,N-디메틸아미노-피리딘 |
DME | = | 1,2-디메톡시에탄 |
DMF | = | 디메틸포름아미드 |
DMSO | = | 디메틸설폭사이드 |
RT | = | 실온 |
TEA | = | 트리에틸아민 |
TFA | = | 트리플루오로아세트산 |
THF | = | 테트라하이드로푸란 |
Claims (65)
- 일반식 (I)의 화합물 또는 그의 약제학적으로 허용되는 염, 에스테르 또는 아미드:상기 식에서,Ra및 Rb는 독립적으로 C1-8알킬, C3-8알케닐, C3-8사이클로알킬, (C3-8사이클로알킬)C1-6알킬이거나, 이들이 결합된 질소와 함께 임의로 3 개 이하의 추가의 헤테로원자를 포함하는 4-7 원 헤테로사이클릴을 형성하며;n은 0-4이고;R1, R2및 R3중 하나는 G이며, 나머지 2 개는 수소 또는 할로이고;G는 하기한 그룹 중 하나로부터 선택된 질소-함유 그룹이며:-OL1Q, -L2Q, -N(L1Q)R5, -L3C(L1Q)R6R7, -C(L1Q)R6R7,여기에서,L1은 C2-6알킬렌, C3-8사이클로알킬렌, C4-6알케닐렌, C4-6알키닐렌, C2-5알카노일, (페닐)C1-6알킬렌, (나프틸)C1-6알킬렌, (C2-5헤테로아릴)C1-6알킬렌, (페녹시)C1-6알킬렌, 또는 (C2-5헤테로아릴옥시)C1-6알킬렌이며;L2는 C1-6알킬렌, C3-8사이클로알킬렌, C3-6알케닐렌, C3-6알키닐렌, C2-5알카노일, (페닐)C1-6알킬렌, (나프틸)C1-6알킬렌, (C1-5헤테로아릴)C1-6알킬렌, (페녹시)C1-6알킬렌, (C1-5헤테로아릴옥시)C1-6알킬렌, 또는 (C1-5헤테로아릴티오)C1-6알킬렌이고;L3는 C1-6알킬렌, C2-6알케닐렌, C2-6알키닐렌, C2-5알카노일, (페닐)C1-6알킬렌, 페닐, 나프틸, (나프틸)C1-6알킬렌, (C1-5헤테로아릴)C1-6알킬렌, (페녹시)C1-6알킬렌, (C1-5헤테로아릴옥시)C1-6알킬렌, 또는 C2-5헤테로아릴이며;L4는 C1-5알킬렌이고;L5는 C1-5알킬렌이며;L6는 C1-5알킬렌이고;L7은 C1-5알킬렌이거나 존재하지 않으며;Q는 -NR8R9또는 적어도 하나의 환 원자 및 임의로 각각의 환에 O, S 및 N으로부터 선택된 1 내지 3 개의 추가의 헤테로원자를 함유하는 비방향족 C2-15헤테로사이클릴 환 시스템이고;R5및 R6는 각각 독립적으로 수소, C1-8알킬, C2-8알케닐, C3-7사이클로알킬, (C3-7사이클로알킬)C1-6알킬렌, C2-15헤테로사이클릴 및 (C2-7헤테로사이클릴)C1-6알킬렌으로부터 선택되며;R7은 H, 하이드록실, 할로, C2-6알콕시이거나, 탄소 결합 L6및 L7(또는 R6에 결합됨)이 이중 결합에 관여하는 경우 존재하지 않으며;R8및 R9는 각각 독립적으로 수소, C1-8알킬, C3-8알케닐, C3-7사이클로알킬, (C3-7사이클로알킬)C1-6알킬렌, C2-15헤테로사이클릴, 페닐, (C2-15헤테로사이클릴) C1-6알킬렌 및 (페닐)C1-6알킬렌으로부터 선택되고;R10은 H, C1-8알킬, C3-8알케닐, C3-7사이클로알킬, (C3-7사이클로알킬)C1-6알킬렌, (C2-15헤테로사이클릴)C1-6알킬렌 또는 (페닐)C1-6알킬렌이며;상기한 알킬, 알킬렌, 알케닐, 알케닐렌, 알키닐, 알키닐렌, 헤테로사이클릴, 사이클로알킬 및 아릴 그룹은 각각 독립적이고 할로, 아미노, 니트로, 하이드록실 및 C1-3알킬로부터 선택된 1 내지 3 개의 치환체에 의해 임의로 치환될 수 있고;Q의 치환체는 카복스아미드, C2-6알킬, C1-8헤테로사이클릴, N(C1-6알킬)(C1-8헤테로사이클릴), NH(C1-8헤테로사이클릴), (C1-8헤테로사이클릴)C1-3알킬렌, O(C1-8헤테로사이클릴), C1-6알콕시, (페닐)C3-6사이클로알킬-O-, 페닐, (페닐)C1-3알킬렌, N(C1-6알킬)[(페닐)C1-3알킬렌] 및 (페닐)C1-3알킬렌-O-로부터 추가로 선택될 수 있으며, 여기서 상기한 헤테로사이클릴, 페닐 및 알킬 그룹은 할로겐, 니트로, 시아노 및 C1-3알킬로부터 독립적으로 선택된 1 내지 3 개의 치환체에 의해 임의로 치환될 수 있다.
- 제 1 항에 있어서, NRaRb가 피페리딜, 메틸피페리딜, 디메틸아미노, 피롤리디닐, 디에틸아미노, 메틸에틸아미노, 에틸프로필아미노 또는 디프로필아미노를 형성하는 화합물.
- 제 2 항에 있어서, NRaRb가 함께 피페리딜, 피롤리디닐 또는 디에틸아미노를 형성하는 화합물.
- 제 3 항에 있어서, NRaRb가 함께 피페리딜 또는 피롤리디닐을 형성하는 화합물.
- 제 1 항에 있어서, R2및 R3중 하나가 G인 화합물.
- 제 5 항에 있어서, R2가 G인 화합물.
- 제 5 항에 있어서, R3이 G인 화합물.
- 제 1 항에 있어서, n이 1 내지 4 인(1 및 4도 포함함) 화합물.
- 제 8 항에 있어서, n이 1인 화합물.
- 제 1 항에 있어서, L1이 C2-3알킬렌인 화합물.
- 제 1 항에 있어서, L2가 C1-6알킬렌, (C1-5헤테로아릴)C1-6알킬렌 또는 -페닐-C1-6알킬렌인 화합물.
- 제 11 항에 있어서, L2가 메틸렌인 화합물.
- 제 1 항에 있어서, L3가 에틸렌, 비닐렌, 에티닐렌 및 페닐렌인 화합물.
- 제 1 항에 있어서, Q가 비방향족 질소-함유 C2-5헤테로사이클릴인 화합물.
- 제 14 항에 있어서, Q가 피페리딜, N-(C1-6알킬)피페라지닐, 피레라지닐, 피롤리닐, 피롤리디닐 및 모르폴리닐로부터 선택된 화합물.
- 제 14 항에 있어서, Q가 각 경우에 헤테로사이클릴, 페닐 및 알킬 그룹이 할로겐, 니트로, 시아노 및 C1-3알킬로부터 독립적으로 선택된 1 내지 3 개의 치환체에 의해 임의로 치환될 수 있는 하이드록실, 카복스아미드, C2-6알킬, C1-8헤테로사이클릴, N(C1-6알킬)(C1-8헤테로사이클릴), NH(C1-8헤테로사이클릴), (C1-8헤테로사이클릴)C1-3알킬렌, C1-8헤테로사이클릴-O-, C1-6알콕시, (C3-6사이클로알킬)-O-, 페닐, (페닐)C1-3알킬렌, N(C1-6알킬)[(페닐)C1-3알킬렌] 및 (페닐)C1-3알킬렌-O-로부터 선택된 1 내지 3 개의 치환체에 의해 임의로 치환될 수 있는 N-모르폴리닐 또는 N-피페리디닐인 화합물.
- 제 16 항에 있어서, Q가 피리딜, 피리미딜, 푸릴, 티오푸릴, 이미다졸릴, (이미다졸릴)C1-6알킬렌, 옥사졸릴, 티아졸릴, 2,3-디하이드로-인돌릴, 벤즈이미다졸릴, 2-옥소벤즈이미다졸릴, (테트라졸릴)C1-6알킬렌, 테트라졸릴, (트리아졸릴)C1-6알킬렌, 트리아졸릴, (피롤릴)C1-6알킬렌 및 피롤릴로부터 선택된 C1-6헤테로사이클릴 그룹을 포함하는 치환체에 의해 치환된 화합물.
- 제 17 항에 있어서, Q가 치환되거나 비치환된 N-모르폴리닐인 화합물.
- 제 1 항에 있어서, Q가, R8또는 R9이 각각 독립적으로 수소, C1-8알킬, C3-8알케닐, C3-7사이클로알킬, (C3-7사이클로알킬)C1-6알킬렌, C2-5헤테로사이클릴, 페닐, (C2-5헤테로사이클릴)C1-6알킬렌 및 (페닐)C1-6알킬렌으로부터 독립적으로 선택된 NR8R9인 화합물.
- 제 19 항에 있어서, R8및 R9중 하나가 수소인 화합물.
- 제 20 항에 있어서, R8이 H이고, R9가 할로, 니트로, 시아노 및 C1-3알킬로부터 선택된 1 내지 3 개의 치환체에 의해 임의로 치환된 방향족 C1-8헤테로사이클릴 또는 페닐인 화합물.
- 제 21 항에 있어서, R9가 페닐, 피리딜, 피리미딜, 푸릴, 티오푸릴, 이미다졸릴, (이미다졸릴)C1-6알킬렌, 옥사졸릴, 티아졸릴, 2,3-디하이드로-인돌릴, 벤즈이미다졸릴, 2-옥소벤즈이미다졸릴, (테트라졸릴)C1-6알킬렌, 테트라졸릴, (트리아졸릴)C1-6알킬렌, 트리아졸릴, (피롤릴)C1-6알킬렌 및 피롤릴인 화합물.
- 제 20 항에 있어서, NRaRb가 함께 피페리딜, 메틸피페리딜, 디메틸아미노, 피롤리디닐, 디에틸아미노, 메틸에틸아미노, 에틸프로필아미노 또는 디프로필아미노를 형성하는 화합물.
- 제 22 항에 있어서, NRaRb가 함께 피페리딜, 피롤리디닐 또는 디에틸아미노를 형성하는 화합물.
- 제 20 항에 있어서, n이 1인 화합물.
- 제 1 항에 있어서 G가 하기 (4) 내지 (7)로부터 선택되는 화합물:(4) L4및 L5가 독립적으로 C2-3알킬렌으로부터 선택된 일반식 (i),(5) L6가 C2-3알킬렌이고 L7이 C2-3알킬렌이거나 존재하지 않는 일반식 (iii);(6) L2가 C1-6알킬렌, 페닐 C1-4알킬렌 또는 (방향족 C1-5헤테로사이클릴)C1-4알킬렌인 L2Q, 및(7) L1이 C2-3알킬렌인 OL1Q.
- 제 26 항에 있어서, G가 하기 (8) 내지 (10)으로부터 선택되는 화합물:(8) L4및 L5가 각각 C2알킬렌인 일반식 (i),(9) L6및 L7이 각각 C2알킬렌인 일반식 (iii),(10) L2가 메틸렌인 L2Q.
- 제 27 항에 있어서, G가 L2Q인 화합물.
- 제 26 항에 있어서, R10이 H, 측쇄 C3-6알킬 또는 벤질인 화합물.
- 제 29 항에 있어서, R10이 이소프로필 또는 벤질인 화합물.
- 제 26 항에 있어서, Q가 비방향족 C2-5헤테로사이클릴인 화합물.
- 제 31 항에 있어서, Q가 피페리딜, N-(C1-6알킬)피페라지닐, 피페라지닐, 피롤리닐, 피롤리디닐 및 모르폴리닐로부터 선택되는 화합물.
- 제 27 항에 있어서, Q가 비방향족 C2-5헤테로사이클릴인 화합물.
- 제 33 항에 있어서, Q가 피페리딜, N-(C1-6알킬)피페라지닐, 피페라지닐, 피롤리닐, 피롤리디닐 및 모르폴리닐로부터 선택되는 화합물.
- 제 34 항에 있어서, Q가 피페리딜, N-(C1-6알킬)피페라지닐, 피페라지닐, 피롤리닐, 피롤리디닐 및 모르폴리닐로부터 선택되는 화합물.
- 제 28 항에 있어서, NRaRb가 함께 피페리딜, 피롤리디닐 또는 디에틸아미노를 형성하는 화합물.
- 제 26 항에 있어서, n이 1인 화합물.
- 제 25 항에 있어서, R7이 하이드록실 또는 할로이거나, L6및 L7중 하나가 R6및 R7이 부착된 탄소원자에 이중 결합을 제공하는 경우 존재하지 않는 화합물.
- 제 19 항에 있어서, 메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-(2-피리딘-2-일-에틸)-아민, 벤질-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 메틸-(1-메틸-피페리딘-4-일)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-4-일메틸-아민, [2-(3,4-디메톡시-페닐)-에틸]-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 메틸-펜에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 디메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 디메틸-{2-[4-(3-피페리딘-1-일-프로폭시)-페녹시]-에틸}-아민, 메틸-펜에틸-[3-(3-피페리딘-1-일-프로폭시)-벤질]-아민 및 디벤질-(3-{2-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피롤-1-일}-프로필)-아민으로부터 선택되는 화합물.
- 제 19 항에 있어서, 인단-1-일-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로헥실-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로프로필-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 피리딘-2-일-[4-(3-피롤리딘-1-일-프로폭시)-벤질]-아민, [4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민, 페닐-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, [3-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민, (4-클로로-페닐)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민 및 (4-클로로-페닐)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민으로부터 선택되는 화합물.
- 제 1 항에 있어서, 4-[3-(3-피페리딘-1-일메틸-페녹시)-프로필]-모르폴린, 1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페리딘, 벤질-메틸-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-아민, 1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필-데카듀테리오-피페리딘, 1-(3-{4-[5-(3-피페리딘-1-일-프로필설파닐)-테트라졸-1-일]-페녹시}-프로필)-피페리딘, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-모르폴린, 2-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4-테트라하이드로-이소퀴놀린, {1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-피리딘-2-일-아민, 1-벤질-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 인단-1-일-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로헥실-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로프로필-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 8-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,4-디옥사-8-아자-스피로[4.5]데칸, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-카복실산 아미드, 메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-(2-피리딘-2-일-에틸)-아민, 벤질-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 4-페닐-1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 1-페닐-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 메틸-펜에틸-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-아민, 2-메틸-1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페리딘, 메틸-(1-메틸-피페리딘-4-일)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, {1-[4-(3-피페리딘-1-일-프로폭시)-벤질]피페리딘-4-일}-피리딘-2-일-(2-피롤리딘-1-일-에틸)-아민, 2-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-에탄올, 1-[3-(4-피롤리딘-1-일메틸-페녹시)-프로필]-피페리딘, 1-{3-[4-(4-벤질리덴-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘, 에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-4-일메틸-아민, 1-{3-[4-(4-벤질-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘, 2-(4-클로로-페닐)-5-[4-(3-피페리딘-1-일-프로폭시)-벤질]-2,5-디아자-바이사이클로[2.2.1]헵탄, 1-[3-(2'-피페리딘-1-일메틸-비페닐-4-일옥시)-프로필]-피페리딘, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-1,3-디하이드로-벤조이미다졸-2-온, 1-(3-{4-[1-(3-피페리딘-1-일-프로필)-1H-피롤-2-일]-페녹시}-프로필)-피페리딘로부터 선택되는 화합물.
- 제 1 항에 있어서, 1-(3-페닐-알릴)-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, [2-(3,4-디메톡시-페닐)-에틸]-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 메틸-펜에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 1-{3-[3-(4-벤질리덴-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘, 4-(4-클로로-페닐)-1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-4-(3-페닐-프로필)-피페리딘, 디메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-1H-벤조이미다졸, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4,5,6-헥사하이드로-[2,3']비피리디닐, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-2,3-디하이드로-1H-인돌, 1-이소프로필-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아자사이클로트리데칸, 1-메틸-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 5-브로모-1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-2,3-디하이드로-1H-인돌, 메틸-펜에틸-[3-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 2-{1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페리딘-2-일}-에탄올, 4-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-모르폴린, 2-[4-(2-피페리딘-1-일-에톡시)-벤질]-1,2,3,4-테트라하이드로-이소퀴놀린, 피리딘-2-일-[4-(3-피롤리딘-1-일-프로폭시)-벤질]-아민, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4-테트라하이드로-퀴놀린, [4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민, 1-[2-(4-피페리딘-1-일메틸-페녹시)-에틸]-피페리딘, 디벤질-(3-{2-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피롤-1-일}-프로필)-아민, 디메틸-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-아민, 페닐-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, [3-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민, 5-(3-피페리딘-1-일-프로폭시)-2-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피리미딘, (4-클로로-페닐)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 1-메틸-4-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페라진, 1-[4-(2-피페리딘-1-일-에톡시)-벤질]-1,2,3,4-테트라하이드로-퀴놀린 및 (4-클로로-페닐)-[3-(3-피페리딘-1-일-프로폭시)-벤질]-아민으로부터 선택되는 화합물.
- 제 1 항에 있어서, 4-[3-(3-피페리딘-1-일메틸-페녹시)-프로필]-모르폴린, 1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페리딘, 벤질-메틸-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-아민, 1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필-데카듀테리오-피페리딘, 1-(3-{4-[5-(3-피페리딘-1-일-프로필설파닐)-테트라졸-1-일]-페녹시}-프로필)-피페리딘, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-모르폴린, 2-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4-테트라하이드로-이소퀴놀린, {1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-피리딘-2-일-아민, 1-벤질-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 인단-1-일-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로헥실-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 사이클로프로필-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 8-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,4-디옥사-8-아자-스피로[4.5]데칸, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-카복실산 아미드, 메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-(2-피리딘-2-일-에틸)-아민, 벤질-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 4-페닐-1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 1-페닐-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 메틸-펜에틸-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-아민, 2-메틸-1-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-피페리딘, 메틸-(1-메틸-피페리딘-4-일)-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, {1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-피리딘-2-일-(2-피롤리딘-1-일-에틸)-아민, 2-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-에탄올, 1-[3-(4-피롤리딘-1-일메틸-페녹시)-프로필]-피페리딘, 1-{3-[4-(4-벤질리덴-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘 및 에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-4-일메틸-아민으로부터 선택되는 화합물.
- 제 1 항에 있어서, 1-{3-[4-(4-벤질-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘, 2-(4-클로로-페닐)-5-[4-(3-피페리딘-1-일-프로폭시)-벤질]-2,5-디아자-비사이클로[2.2.1]헵탄, 1-[3-(2'-피페리딘-1-일메틸-비페닐-4-일옥시)-프로필]-피페리딘, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-1,3-디하이드로-벤조이미다졸-2-온, 1-(3-{4-[1-(3-피페리딘-1-일-프로필)-1H-피롤-2-일]-페녹시}-프로필)-피페리딘, 1-(3-페닐-알릴)-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, [2-(3,4-디메톡시-페닐)-에틸]-메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 메틸-펜에틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 1-{3-[3-(4-벤질리덴-피페리딘-1-일메틸)-페녹시]-프로필}-피페리딘, 4-(4-클로로-페닐)-1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-올, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-4-(3-페닐-프로필)-피페리딘, 디메틸-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-1H-벤조이미다졸, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4,5,6-헥사하이드로-[2,3']비피리디닐, 1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-2,3-디하이드로-1H-인돌, 1-이소프로필-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아자사이클로트리데칸, 1-메틸-4-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페라진, 5-브로모-1-{1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-피페리딘-4-일}-2,3-디하이드로-1H-인돌, 메틸-펜에틸-[3-(3-피페리딘-1-일-프로폭시)-벤질]-아민, 2-{1-[3-(4-피페리딘-1-일 메틸-페녹시)-프로필]-피페리딘-2-일}-에탄올, 4-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-모르폴린, 2-[4-(2-피페리딘-1-일-에톡시)-벤질]-1,2,3,4-테트라하이드로-이소퀴놀린, 피리딘-2-일-[4-(3-피롤리딘-1-일-프로폭시)-벤질]-아민, 1-[4-(3-피페리딘-1-일-프로폭시)-벤질]-1,2,3,4-테트라하이드로-퀴놀린, [4-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민, 1-[2-(4-피페리딘-1-일메틸-페녹시)-에틸]-피페리딘, 디벤질-(3-{2-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피롤-1-일}-프로필)-아민, 디메틸-[3-(4-피페리딘-1-일메틸-페녹시)-프로필]-아민, 페닐-[4-(3-피페리딘-1-일-프로폭시)-벤질]-아민 및 [3-(3-피페리딘-1-일-프로폭시)-벤질]-피리딘-2-일-아민으로부터 선택되는 화합물.
- 제 1 항에 있어서, 1-이소프로필-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페라진, 1-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페라진 하이드로클로라이드, 1-벤질-4-[4-(3-피롤리딘-1-일-프로폭시)-페닐]-피페라진, 1-[4-(3-피롤리딘-1-일-프로폭시)-페닐]-피페라진 하이드로클로라이드 및 1-벤질-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페라진으로부터 선택되는 화합물.
- 제 26 항에 있어서, 1-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페라진, 1-이소프로필-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페라진, 1-벤질-4-[4-(3-피롤리딘-1-일-프로폭시)-페닐]-피페라진 및 1-[4-(3-피롤리딘-1-일-프로폭시)-페닐]-피페라진로부터 선택되는 화합물.
- 제 1 항에 있어서, 1-{3-[2'-(1-이소프로필-피페리딘-4-일)-비페닐-4-일옥시]-프로필}-피페리딘, 1-(3-{4-[2-(1-메틸-피롤리딘-2-일)-에틸]-페녹시}-프로필)-피페리딘 및 1-{3-[4-(1-이소프로필-피페리딘-4-일메틸)-페녹시]-프로필}-피페리딘으로부터 선택되는 화합물.
- 제 1 항에 있어서, 1-{3-[4-(1-메틸-피롤리딘-2-일)-페녹시]-프로필}-피페리딘, 1-벤질-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페리딘-4-올 및 1-이소프로필-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페리딘-4-올로부터 선택되는 화합물.
- 제 26 항에 있어서, 1-{3-[4-(1-메틸-피롤리딘-2-일)-페녹시]-프로필}-피페리딘 및 1-벤질-4-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피페리딘-4-올로부터 선택되는 화합물.
- 제 1 항에 있어서, {3-푸란-2-일-3-[4-(3-피페리딘-1-일-프로폭시)-페닐]-프로필}-디메틸-아민, 4-{3-[4-(3-피페리딘-1-일-프로폭시)-페닐]-3-피리미딘-2-일-프로필}-모르폴린, 4-{4,4,4-트리플루오로-3-[4-(3-피페리딘-1-일-프로폭시)-페닐]-부틸}-모르폴린 및 4-{4,4,4-트리플루오로-3-[4-(3-피페리딘-1-일-페녹시)-프로필]-부틸}-모르폴린으로부터 선택되는 화합물.
- 제 1 항에 있어서, (2-모르폴린-4-일-에틸)-[4-(3-피페리딘-1-일-프로폭시)-페닐]-피리딘-2-일-아민, 이소프로필-(2-모르폴린-4-일-에틸)-[4-(3-피페리딘-1-일-프로폭시)-페닐]-아민 및 (2-모르폴린-4-일-에틸)-[4-(3-피페리딘-1-일-프로폭시)-페닐]-트리아졸-2-일메틸-아민으로부터 선택되는 화합물.
- 제 1 항, 제 26 항, 제 27 항, 제 41 항, 제 44 항 또는 제 48 항에 따른 화합물 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- 제 1 항, 제 26 항, 제 27 항 또는 제 41 항에 있어서, PET 또는 SPECT에 의해 검출가능하도록 동위원소 표지된 화합물.
- 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 히스타민H3수용체 활성 저해를 필요로 하는 대상에게 투여하는 것으로 포함하여, 대상에서 히스타민 H3수용체 활성을 저해하는 방법.
- 치료학적 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 대상에게 투여하는 것으로 포함하여, 히스타민 H3수용체 활성에 의해 조절되는 질병이나 이상을 갖는 대상을 치료하는 방법.
- 제 55 항에 있어서, 질환이나 이상이 수면/기상 장애, 각성/불면증 장애, 편두통, 천식, 치매, 경증 인지 손상(치매전), 알츠하이머병, 간질, 기면증, 식사 장애, 운동 장애, 현기증, 주의 결핍 과잉행동 장애, 학습 장애, 기억 보유 장애, 정신분열증, 비충혈, 알레르기성 비염, 및 상부 기도 알레르기 반응으로 구성된 그룹으로부터 선택되는 방법.
- (a) 대상에게 병용 유효량의 히스타민 H1수용체 길항제 화합물을 투여하고, (b) 대상에게 병용 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 투여하는 것을 포함하며, 병용 치료 유효량의 상기 화합물들을 제공하는, 히스타민 H1수용체 및 히스타민 H3수용체로부터 선택되는 적어도 하나의 수용체에 의해 조절되는 질환이나 이상을 치료하는 방법.
- 제 57 항에 있어서, 히스타민 H1수용체 길항제와 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물이 동일한 제형으로 존재하는 방법.
- (a) 대상에게 병용 유효량의 히스타민 H2수용체 길항제 화합물을 투여하고, (b) 대상에게 병용 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 투여하는 것을 포함하며, 병용 치료 유효량의 상기 화합물들을 제공하는, 히스타민 H2수용체 및 히스타민 H3수용체로부터 선택되는 적어도 하나의 수용체에 의해 조절되는 질환이나 이상을 치료하는 방법.
- 제 59 항에 있어서, 히스타민 H2수용체 길항제와 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물이 동일한 제형으로 존재하는 방법.
- 치료 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 대상에게 투여하는 것을 포함하여, 수면/기상 장애, 기면증, 및 각성/불면증 장애로 구성된 그룹으로부터 선택되는 질환이나 이상을 치료하는 방법.
- 치료 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 대상에게 투여하는 것을 포함하여, 주의 결핍 과잉행동 장애(ADHD)를 치료하는 방법.
- 치료 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 대상에게 투여하는 것을 포함하여, 치매, 경증 인지 손상(치매전), 인지 부전, 정신분열증, 우울증, 조병, 양극성 장애, 및 학습 및 기억 장애로 구성된 그룹으로부터 선택되는 하나 이상의 장애나 이상을 치료하는 방법.
- 치료 유효량의 제 1 항, 제 26 항, 제 27 항 또는 제 41 항의 화합물을 대상에게 투여하는 것을 포함하여, 상부 기도 알레르기 반응, 비 충혈, 또는 알레르기성 비염을 치료하거나 예방하는 방법.
- 양전자 방출 단층촬영(PET) 분자 탐침으로서18F-표지된 제 1 항의 화합물을 사용하는 것을 포함하여, 히스타민 H3수용체에 의해 매개되는 장애를 연구하는 방법.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22376800P | 2000-08-08 | 2000-08-08 | |
US60/223,768 | 2000-08-08 | ||
US09/922,631 US7186732B2 (en) | 2000-08-08 | 2001-08-06 | Non-imidazole aryloxyalkylamines |
PCT/US2001/024655 WO2002012214A2 (en) | 2000-08-08 | 2001-08-06 | Non-imidazole aryloxyalkylamines as h3 receptor ligands |
US09/922,631 | 2001-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030038692A true KR20030038692A (ko) | 2003-05-16 |
KR100819381B1 KR100819381B1 (ko) | 2008-04-04 |
Family
ID=26918111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037001878A KR100819381B1 (ko) | 2000-08-08 | 2001-08-06 | 비-이미다졸 아릴옥시알킬아민 |
Country Status (19)
Country | Link |
---|---|
US (4) | US7186732B2 (ko) |
EP (1) | EP1313721B1 (ko) |
JP (1) | JP5279161B2 (ko) |
KR (1) | KR100819381B1 (ko) |
CN (1) | CN1468227A (ko) |
AT (1) | ATE319696T1 (ko) |
AU (2) | AU8473301A (ko) |
BR (1) | BRPI0113162B8 (ko) |
CA (1) | CA2418369A1 (ko) |
CZ (1) | CZ2003685A3 (ko) |
DE (1) | DE60117814T2 (ko) |
DK (1) | DK1313721T3 (ko) |
ES (1) | ES2260276T3 (ko) |
HK (1) | HK1053110A1 (ko) |
HU (1) | HU230055B1 (ko) |
MX (1) | MXPA03001267A (ko) |
PL (1) | PL360886A1 (ko) |
PT (1) | PT1313721E (ko) |
WO (1) | WO2002012214A2 (ko) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
WO2004037257A1 (en) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
BRPI0315644B8 (pt) | 2002-10-23 | 2021-05-25 | Janssen Pharmaceutica Nv | compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos |
JPWO2004089410A1 (ja) * | 2003-04-03 | 2006-07-06 | 協和醗酵工業株式会社 | 神経因性疼痛の予防及び/または治療剤 |
GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
FR2856596B1 (fr) * | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
US20050239791A1 (en) * | 2004-04-07 | 2005-10-27 | Hutchison Alan J | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
AU2006228690A1 (en) | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
EP1707204A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands |
EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
ES2574014T3 (es) * | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
DK1948607T3 (da) | 2005-09-16 | 2010-07-26 | Janssen Pharmaceutica Nv | Cyclopropylaminer med histamin-H3-receptormodulatorer |
WO2007045989A1 (en) * | 2005-10-20 | 2007-04-26 | Pfizer Limited | Pyridyl derivatives useful as h3 ligands |
US7943605B2 (en) | 2005-10-27 | 2011-05-17 | Ucb Pharma S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
JP2009514846A (ja) * | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
EP1948605A2 (en) * | 2005-11-17 | 2008-07-30 | Arena Pharmaceuticals, Inc. | Modulators of the h3 receptor useful for the treatment of disorders related thereto |
US20100009969A1 (en) * | 2006-07-27 | 2010-01-14 | Ucb Pharma, S.A. | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands |
EA200901378A1 (ru) * | 2007-04-19 | 2010-04-30 | Юсб Фарма С.А. | Лиганды гистаминового рецептора н, содержащие циклобутоксигруппу |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
US10491458B2 (en) * | 2013-01-31 | 2019-11-26 | Dell Products L.P. | System and method for reporting peer-to-peer transfer events |
HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
CN107382909A (zh) * | 2016-05-16 | 2017-11-24 | 复旦大学 | 选择性ERβ受体调节剂及其药用用途 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3317538A (en) * | 1965-10-22 | 1967-05-02 | American Home Prod | 4, 4'-diamino-butyrophenones |
US3919231A (en) * | 1974-06-17 | 1975-11-11 | Morton Norwich Products Inc | Series of 5-aryl-2-furamidines |
US5182291A (en) * | 1986-02-14 | 1993-01-26 | Sanofi | Pyrozala-pyridyl aminoabkoxyphenol compounds |
US4833149A (en) * | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
JPH0259548A (ja) * | 1988-08-24 | 1990-02-28 | Hokuriku Seiyaku Co Ltd | アミド化合物 |
US5236917A (en) * | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
US5580883A (en) * | 1990-03-26 | 1996-12-03 | Takeda Chemical Industries, Ltd. | Aminobenzene compounds to prevent nerve cell degradation |
US5352707A (en) | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
US5217986A (en) | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
CA2133461A1 (en) | 1992-04-01 | 1993-10-14 | Graham J. Durant | 4-[4'piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof |
US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
FR2708609B1 (fr) | 1993-07-29 | 1995-10-20 | Sanofi Elf | Dérivés de méthylguanidine, leurs procédés de préparation ainsi que les compositions en contenant. |
ATE234290T1 (de) | 1993-11-15 | 2003-03-15 | Schering Corp | Phenylalkyl-imidazole als h3-rezeptor- antagonisten |
US5580523A (en) | 1994-04-01 | 1996-12-03 | Bard; Allen J. | Integrated chemical synthesizers |
US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
GB2303628A (en) * | 1995-07-27 | 1997-02-26 | Lilly Co Eli | 5-Hydroxy- and 5-phenyl-substituted 1-[4-(aminoalkoxy)phenyl]-2-phenylbenzene derivatives for the treatment of post menopausal symptoms and intermediates |
PL186204B1 (pl) | 1995-11-09 | 2003-11-28 | Sanofi Synthelabo | Pochodne 5-fenylo-3-(piperydyn-4-ylo)-1,3,4-oksadiazol-2(3H)-onu do stosowania jako ligandy receptora 5-HT lub H |
DE69819539T2 (de) * | 1997-05-01 | 2004-09-30 | Eli Lilly And Co., Indianapolis | Antithrombotische mittel |
US6200536B1 (en) | 1997-06-26 | 2001-03-13 | Battelle Memorial Institute | Active microchannel heat exchanger |
US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
WO1999059586A1 (en) * | 1998-05-19 | 1999-11-25 | Regents Of The University Of California | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
DE19920161A1 (de) | 1998-11-06 | 2000-05-25 | Atotech Deutschland Gmbh | Verfahren zum Herstellen von Mikrobauteilen mit Strömungskanälen |
DE60017702T2 (de) | 1999-03-03 | 2006-04-06 | Symyx Technologies, Inc., Santa Clara | Chemische verfahrensmikrosysteme zur evaluierung heterogener katalysatoren und ihre verwendung |
EP1230224B1 (de) * | 1999-11-04 | 2004-12-29 | Basilea Pharmaceutica AG | Substituierte 5-benzyl-2,4-diaminopyrimidine |
EP1286761A2 (en) | 2000-05-24 | 2003-03-05 | Cellular Process Chemistry Inc. | Modular chemical production system incorporating a microreactor |
ES2261454T3 (es) | 2000-08-08 | 2006-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Compuestos biciclicos como ligandos del receptor h3. |
AU8112101A (en) * | 2000-08-08 | 2002-02-18 | Ortho Mcneil Pharm Inc | Non-imidazole aryloxypiperidines |
-
2001
- 2001-08-06 AT AT01963813T patent/ATE319696T1/de active
- 2001-08-06 AU AU8473301A patent/AU8473301A/xx active Pending
- 2001-08-06 CZ CZ2003685A patent/CZ2003685A3/cs unknown
- 2001-08-06 EP EP01963813A patent/EP1313721B1/en not_active Expired - Lifetime
- 2001-08-06 ES ES01963813T patent/ES2260276T3/es not_active Expired - Lifetime
- 2001-08-06 DK DK01963813T patent/DK1313721T3/da active
- 2001-08-06 CA CA002418369A patent/CA2418369A1/en not_active Abandoned
- 2001-08-06 US US09/922,631 patent/US7186732B2/en not_active Expired - Lifetime
- 2001-08-06 JP JP2002518191A patent/JP5279161B2/ja not_active Expired - Lifetime
- 2001-08-06 PT PT01963813T patent/PT1313721E/pt unknown
- 2001-08-06 KR KR1020037001878A patent/KR100819381B1/ko active IP Right Grant
- 2001-08-06 PL PL01360886A patent/PL360886A1/xx not_active Application Discontinuation
- 2001-08-06 DE DE60117814T patent/DE60117814T2/de not_active Expired - Lifetime
- 2001-08-06 WO PCT/US2001/024655 patent/WO2002012214A2/en active IP Right Grant
- 2001-08-06 MX MXPA03001267A patent/MXPA03001267A/es active IP Right Grant
- 2001-08-06 HU HU0302959A patent/HU230055B1/hu unknown
- 2001-08-06 AU AU2001284733A patent/AU2001284733B2/en not_active Ceased
- 2001-08-06 CN CNA018168094A patent/CN1468227A/zh active Pending
- 2001-08-06 BR BRPI0113162A patent/BRPI0113162B8/pt not_active IP Right Cessation
-
2003
- 2003-07-23 HK HK03105330.5A patent/HK1053110A1/zh unknown
-
2006
- 2006-06-15 US US11/453,422 patent/US7429586B2/en not_active Expired - Lifetime
-
2008
- 2008-08-20 US US12/194,653 patent/US20080306085A1/en not_active Abandoned
-
2009
- 2009-08-14 US US12/541,447 patent/US20100004241A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1313721T3 (da) | 2006-06-26 |
AU8473301A (en) | 2002-02-18 |
KR100819381B1 (ko) | 2008-04-04 |
DE60117814T2 (de) | 2006-11-02 |
HU230055B1 (hu) | 2015-06-29 |
JP2004505960A (ja) | 2004-02-26 |
EP1313721A2 (en) | 2003-05-28 |
US7429586B2 (en) | 2008-09-30 |
CA2418369A1 (en) | 2002-02-14 |
US20100004241A1 (en) | 2010-01-07 |
WO2002012214A2 (en) | 2002-02-14 |
PT1313721E (pt) | 2006-06-30 |
BRPI0113162B1 (pt) | 2016-06-28 |
EP1313721B1 (en) | 2006-03-08 |
MXPA03001267A (es) | 2004-07-30 |
WO2002012214A3 (en) | 2002-06-20 |
DE60117814D1 (de) | 2006-05-04 |
US20080306085A1 (en) | 2008-12-11 |
HUP0302959A2 (hu) | 2003-12-29 |
AU2001284733B2 (en) | 2006-11-02 |
CN1468227A (zh) | 2004-01-14 |
BR0113162A (pt) | 2004-04-06 |
BRPI0113162B8 (pt) | 2021-05-25 |
US20020065278A1 (en) | 2002-05-30 |
CZ2003685A3 (cs) | 2003-08-13 |
US7186732B2 (en) | 2007-03-06 |
HUP0302959A3 (en) | 2006-04-28 |
PL360886A1 (en) | 2004-09-20 |
HK1053110A1 (zh) | 2003-10-10 |
ATE319696T1 (de) | 2006-03-15 |
ES2260276T3 (es) | 2006-11-01 |
JP5279161B2 (ja) | 2013-09-04 |
US20060235049A1 (en) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100819381B1 (ko) | 비-이미다졸 아릴옥시알킬아민 | |
KR100852362B1 (ko) | 비-이미다졸 아릴옥시피페리딘 | |
AU2001284733A1 (en) | Non-imidazole aryloxyalkylamines as H3 receptor ligands | |
AU2001281121A1 (en) | Non-imidazole aryloxypiperidines as H3 receptor ligands | |
KR101067732B1 (ko) | 피페라지닐 및 디아자파닐 벤즈아미드 및 벤즈티오아미드 | |
EP1311499B1 (en) | Bicyclic compounds as h3 receptor ligands | |
EP1451167B1 (en) | Phenylalkynes | |
US20040002604A1 (en) | Phenylalkynes | |
KR20050086801A (ko) | 페닐알킨 유도체의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130305 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140220 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150224 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160303 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190227 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200227 Year of fee payment: 13 |